Delivery of miRNA-29b Using R9-LK15, a Novel Cell-Penetrating Peptide, Promotes Osteogenic Differentiation of Bone Mesenchymal Stem Cells

Figure 3

Cytotoxic effects of R9-LK15/miR-29b nanocomplexes on BMSCs. (a) LIVE/DEAD assay of untreated BMSCs (Con) and those treated with miR-29b, Lipo, R9-LK15, Lipo/miR-29b nanocomplexes, and R9-LK15/miR-29b nanocomplexes for 72 h. (b) The percentage of dead cells was calculated. Data are the mean ± SD of triplicate experiments. < 0.05. (c) CCK-8 assay of untreated BMSCs (Control) and those treated with miR-29b, Lipo, R9-LK15, Lipo/miR-29b nanocomplexes, and R9-LK15/miR-29b nanocomplexes for 2, 4, and 6 days. Data are the mean ± SD of triplicate experiments. < 0.05, < 0.01.

(a)

(b)

(c)